Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.
about
Review on the Applications and Molecular Mechanisms of Xihuang Pill in Tumor TreatmentBRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb useInhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs.Bone metastases in patients with small cell lung carcinoma: rate of development, early versus late onset, modality of treatment, and their impact on survival. A single-institution retrospective cohort study.
P2860
Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Molecular target therapy for b ...... denosumab, a RANKL inhibitor.
@en
type
label
Molecular target therapy for b ...... denosumab, a RANKL inhibitor.
@en
prefLabel
Molecular target therapy for b ...... denosumab, a RANKL inhibitor.
@en
P2093
P2860
P1476
Molecular target therapy for b ...... denosumab, a RANKL inhibitor.
@en
P2093
Antonio Russo
Giuseppe Bronte
Kostantinos Papadimitriou
Luis E Raez
Noemí Reguart
Rosario García Campelo
P2860
P356
10.1517/14712598.2013.843667
P407
P577
2013-10-28T00:00:00Z